On April 28, A-share listed company YHLO (688575. SH) released its annual performance report for 2021. From January 1 to December 31, 2021, the company achieved an operating revenue of 1.178 billion CNY, a year-on-year increase of 17.91%, a net profit of 205 million CNY, a year-on-year decrease of 2.75%, and the basic earnings per share of 0.53 CNY. Among them, in vitro diagnosis revenue was 1.134 billion CNY, a year-on-year increase of 17.71%, and other business revenue was 44.3704 million CNY. During the reporting period, the total assets of the company at the end of the period were 2.138 billion CNY, the operating profit was 227 million CNY, the accounts receivable was 245 million CNY, the net cash flow from operating activities was 260 million CNY, and the cash received from selling goods and providing labor services was 1.331 billion CNY.

At the same time, the company released the performance forecast for Q1, 2022. It has expected that from January 1 to March 31, 2022, the net profit will be 45 to 500 million CNY, with an increase of 1094.75% to 1227.50%. The performance in the same period of last year: the net profit will be 37.6649 million CNY. Regarding to the reasons of performance for Q1, the company announced that at the end of 2021 to the end of the reporting period, the COVID-19 antigen detection kit (colloidal gold method) has successively obtained the CE mark from EU, PMDA certification from Japan and FDA certificate from US. COVID-19 relevant products sold in Europe, Japan, Hong Kong and other regions, and the sales revenue of this product has increased, As a result, the company's performance in Q1 achieved a significant increase over the same period last year.

About YHLO

(CACLP 2022 Booth No：A4-2109)

YHLO is an innovative and steadfastly growing company of immunoassay solutions headquartered in Shenzhen, China, specialized in developing, manufacturing and distributing in-vitro diagnostic instruments and reagents by a team of experienced scientists and engineers. In May of 2021, YHLO has successfully launched IPO and listed on Shanghai Stock Exchange (Stock code: 688575).

To be a reliable and respected IVD enterprise, YHLO has put extensive investments in R&D and firmly associated with the top-tier universities, medical schools and research institutions worldwide on scientific studies. With over a decade's continuous development expertise in immunoassays solution, YHLO may provide a broad range of instruments (based on Chemiluminescence, ELISA, Immunoblot and Immunofluorescnce methodologies) with patented technologies and outstanding features, as well as a comprehensive total solutions with portfolios in fertility and reproductive health, diabetes, infectious diseases, autoimmune disorders and other novel assays on rare diseases analysis.

YHLO` s premium quality management has been certified by international standards, ISO 9001:2015, ISO 13485:2016, KGMP of Korea, TGA of Australia, etc. To date, YHLO has a global presence by nearly 100 countries around the world, our strategic alliances with multinational corporations enable us to be more competitive. Moreover, YHLO has in-depth cooperation with oversea research partners in Europe, USA, Japan and Australia, with aim of developing advanced technologies and create more medical value for health and vitality of people all over the world.